Date: 2014-07-02
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Medimmune (USA - global biologics arm of AstraZeneca (UK), AIMM Therapeutics (The Netherlands)
Product: MEDI8897
Action
mechanism: MEDI8897 originated from AIMM’s D25 antibody. D25 was developed from immortalized B cells of an individual exposed to RSV utilizing AIMM’s proprietary antibody technology platform. Preclinical studies have shown that D25 neutralizes RSV with high efficiency by recognizing a unique epitope on the prefusion structure of the F protein expressed on the virus coat.
Disease: respiratory syncytial virus (RSV) infections in young, at risk children
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On July 2, 2014, AIMM Therapeutics, a leading human therapeutic antibody company, announced that its partner MedImmune, the global biologics unit of AstraZeneca, has initiated phase I clinical studies with MEDI8897, a best-in-class antibody for the treatment of respiratory syncytial virus (RSV) infections in young, at risk children. MEDI8897 originated from AIMM’s D25 antibody. Under the terms of their partnering agreement, AIMM will receive a non-disclosed milestone payment from MedImmune.
